Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2011-09-30
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 35
- Registration Number
- NCT01338909
- Locations
- 🇬🇷
Patras University Hospital, Patras, Greece
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
- Conditions
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Ospedale Misericordia e Dolce
- Target Recruit Count
- 50
- Registration Number
- NCT01335048
- Locations
- 🇮🇹
Cardiology Department, Ospedale Misericordia e Dolce, Prato, Italy
Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Stiftung Institut fuer Herzinfarktforschung
- Target Recruit Count
- 63
- Registration Number
- NCT01327534
- Locations
- 🇩🇪
Klinikum Ludwigshafen, Med. Klinik B, Ludwigshafen, Germany
🇩🇪Charité Campus Benjamin Franklin, Med. Klinik II, Berlin, Germany
🇫🇷Hospital Pitie-Salpetriere, Paris, France
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
- First Posted Date
- 2011-03-30
- Last Posted Date
- 2016-01-07
- Target Recruit Count
- 1187
- Registration Number
- NCT01325935
- Locations
- 🇯🇵
Kimitsu Chuo Hospital, Kisarazu City, Chiba, Japan
🇯🇵Fukui Cardiovascular Center, Fukui City, Fukui, Japan
🇯🇵Fukuoka City Medical Association Hospital, Fukuoka City, Fukuoka, Japan
Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment
- Conditions
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 25
- Registration Number
- NCT01304472
- Locations
- 🇬🇷
Dimitrios Alexopoulos, Patras, Greece
🇬🇷Patras University Hospital Cardiology Department, Patras, Greece
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 801
- Registration Number
- NCT01294462
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Investigation of the Athero-Protective Effects of Clopidogrel
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 48
- Registration Number
- NCT01283282
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT01263093
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT01260584
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
🇺🇸The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States
🇺🇸Sanai Center for Thrombosis Research, Baltimore, Maryland, United States
Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56
- Conditions
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- The TIMI Study Group
- Target Recruit Count
- 335
- Registration Number
- NCT01235351
- Locations
- 🇺🇸
TIMI Study Group, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.